NHS Now Covers New Ovarian Cancer Drug After 20 Years With No New Options

On June 4, the NHS announced it would pay for a new cancer drug called mirvetuximab soravtansine, also known as Elahere. This is the first brand-new ovarian cancer treatment the NHS has covered in over 20 years. The drug helps women whose ovarian cancer has stopped responding to standard chemotherapy — a situation doctors call platinum-resistant cancer.

How the Drug Works

Ovarian cancer cells often have a marker on their surface called folate receptor-alpha. Think of it like a lock specific to certain cancer cells. Mirvetuximab soravtansine is designed to find and attach to that lock, then deliver poison directly inside the cancer cell. This targeted approach means it mainly affects cancer cells, not healthy ones.

The drug was tested in a trial called MIRASOL. Women who received it stayed cancer-free for an average of 5.62 months before their disease got worse. Women who received standard chemotherapy instead lasted 3.98 months. In other words, the new drug delayed cancer progression by about 35% longer.

The Approval Story

Getting a drug approved in Britain involves several steps. The MHRA (the government agency that approves medicines) had already said yes to Elahere. But the NHS — which pays for treatments — needed to decide separately whether it was worth the cost.

An organization called NICE evaluated the drug and initially said no. They thought the evidence didn't prove it was worth what AbbVie, the drug's maker, was charging. But then something changed. NHS England announced it would pay for the drug anyway, suggesting the manufacturer had agreed to a lower price. The exact terms were kept private.

This kind of back-and-forth has become more common. Health systems worldwide struggle with the same problem: cancer drugs are very expensive, but patients need them.

Why This Matters

Ovarian cancer is stubborn. When a woman's cancer stops responding to chemotherapy drugs containing platinum, doctors have very few options left. About 25 to 30 percent of women with ovarian cancer hit this point at their first recurrence. Getting treatment becomes harder from there.

The drug works by using something called an antibody-drug conjugate — a new type of weapon against cancer. Similar approaches have already worked for breast cancer and other tumors. Folate receptor-alpha targeting makes sense for ovarian cancer because many ovarian cancer cells have this marker.

What Happens Next

The NHS will need to set up the machinery to use this drug properly. For example, not all hospitals currently test ovarian cancer cells for folate receptor-alpha. That test will need to become routine. Hospitals will also need to train staff on how to give the drug and what side effects to watch for, since it works differently than traditional chemotherapy.

The Bigger Picture

The broader context here is that the NHS is finding new ways to pay for expensive cancer drugs even when the traditional cost-benefit analysis says no. As healthcare budgets tighten everywhere, that pattern may reshape how drug companies and health systems negotiate. It suggests that for rare cancers with no good alternatives, the rules may be changing — moving away from strict price-per-benefit calculations toward more emphasis on patient access.

For drug makers, this approval signals that antibody-drug conjugates are worth investing in, especially for smaller patient populations where fewer options exist. It also shows that persistence pays off: even an initial rejection from NICE doesn't mean the end of the road.